Mini-Focus on TAVIClinical ResearchA 3-Center Comparison of 1-Year Mortality Outcomes Between Transcatheter Aortic Valve Implantation and Surgical Aortic Valve Replacement on the Basis of Propensity Score Matching Among Intermediate-Risk Surgical Patients
Key Words
Abbreviations and Acronyms
Cited by (0)
Dr. Piazza has served as consultant for Medtronic, HighLife, and CardiaAQ; and steering committee member for the SURTAVI trial. Dr. van Mieghem has served as study chair and steering committee member for the SURTAVI trial. Dr. Wenaweser has served as proctor for Medtronic and Edwards Lifesciences; is a consultant for Biotronik; has received honoraria/lecture fees from Medtronic and Edwards Lifesciences; and has received honoraria from Biotronik. Dr. Bleiziffer has served as consultant for Medtronic and Edwards Lifesciences; and as a proctor for Medtronic and JenaValve. Dr. de Jaegere has served as consultant for Medtronic. Dr. Kappetein has served as principal investigator for the SURTAVI trial. Dr. Lange has served on the advisory board and as consultant for Medtronic; and principal investigator for the SURTAVI trial. Dr. Serruys has served as Study Chair for the SURTAVI trial. Dr. Windecker has served as principal investigator for the SURTAVI trial; been supported by grants to the institution from Medtronic, Edwards Lifesciences, Abbott, Cordis, Biotronik, Boston Scientific, Biosensors, and St. Jude; and has received lecture fees from Edwards Lifesciences and Medtronic. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Dr. Piazza and Dr. Kalesan contributed equally to this work.